Intelligence · Patents
Patents expiring in 2044
Annual patent cliff calendar for 2044 — US pharmaceutical patents by expiration date.
- Patents
- 1,766
Quick answer
1,766 indexed pharmaceutical patents have expiration dates in 2044. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 12116596
Method and apparatus for improved mesenchymal stem cell harvesting
granted -
US 12116606
Complement factor I-related compositions and methods
granted -
US 12116622
Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
granted -
US 12116637
Compositions and methods for detecting and treating high grade subtypes of uterine cancer
granted -
US 12116635
Methods for detecting and treating cancers having adenosine pathway activation
granted -
US 12115156
Compositions of CXCR4 inhibitors and methods of preparation and use
granted -
US 12115216
Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof
granted -
US 12116405
Arthritis treatment
granted -
US 12115254
Methods of use of emulsion formulations of an NK-1 receptor antagonist
granted -
US 12115150
Biomarkers of coronavirus pneumonia
granted -
US 12115031
Dental mill blank and dental prosthesis
granted -
US 12116573
Targeting ligands for therapeutic compounds
granted -
US 12116354
RIP1 inhibitory compounds and methods for making and using the same
granted -
US 12116604
Transposase polypeptides and uses thereof
granted -
US 12116597
Autophagy as a therapeutic target for intracranial aneurysm
granted -
US 12116375
Compositions and methods for treating cancer
granted -
US 12115225
GLP-1 receptor ligand moiety conjugated oligonucleotides and uses thereof
granted -
US 12116346
Human plasma kallikrein inhibitors
granted -
WO 2024216080
RÉGIMES IMMUNOSUPPRESSEURS ET PROCÉDÉS ASSOCIÉS
granted -
US 12122815
GIP receptor agonist peptide compounds and uses thereof
granted -
US 12122837
Oncostatin M receptor antigen binding proteins
granted -
US 12122853
Compositions and methods of inhibiting the binding of plasma IGG autoantibodies to serotonin 2A receptor
granted -
US 12123012
Methods and compositions for nucleic acid and protein payload delivery
granted -
US 12123001
Methods of treating liver diseases with phosphodiesterase 3B (PDE3B) inhibitors
granted -
US 12123035
PH20 polypeptide variants, formulations and uses thereof
granted -
US 12121571
Recombinant L-asparaginase
granted -
US 12121542
BCMA chimeric antigen receptor based on single domain antibody and use thereof
granted -
US 12121532
Modified antisense oligomers for exon inclusion in spinal muscular atrophy
granted -
US 12122843
High affinity monoclonal antibodies targeting glypican-1 and methods of use
granted -
US 12121567
Methods to treat mucopolysaccharidosis type II or deficiency in iduronate-2-sulfatase using a recombinant adeno-associated virus (AAV) vector encoding iduronate-2-sulfatase
granted -
US 12123015
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
granted -
US 12121569
Methods and compositions for CNS delivery of iduronate-2-sulfatase
granted -
US 12121525
Methods for treating GI syndrome and graft versus host disease
granted -
US 12121526
Targeting NCCA-ATP channel for organ protection following ischemic episode
granted -
US 12121541
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
granted -
US 12121540
CBL inhibitors and compositions for use in adoptive cell therapy
granted -
US 12121523
Method of treatment of attention deficit/hyperactivity disorder (ADHD)
granted -
US 12121828
Systems and methods of isolation of gallium-68
granted -
US 12121288
Combination tumor treatment
granted -
US 12122846
Chimeric antigen receptor for tumor targeting
granted -
US 12121522
Methods of treating cancer with an mTOR inhibitor
granted -
US 12122811
BDNF mimetic peptide amphiphiles
granted -
US 12122773
Crystalline hydrate of a JAK inhibitor compound
granted -
US 12121608
Biodegradable implant for sustained trans-nasal delivery of therapeutic agents to the brain
granted -
US 12121580
Antibacterial photodynamic therapy using copper-cysteamine nanoparticles
granted -
US 12121503
Antiviral treatments
granted -
US 12123002
Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
granted -
US 12122998
Materials and methods for treatment of usher syndrome type 2A and/or non-syndromic autosomal recessive retinitis pigmentosa (ARRP)
granted
Frequently asked questions
How many pharma patents expire in 2044?
1,766 published patents in our USPTO index have expiration dates falling in calendar year 2044.